Imunon, Inc. (IMNN) Stock Analysis & Investment Frameworks
Imunon, Inc. (IMNN) stock analysis on Invetso. Review Imunon, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Imunon, Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Imunon, Inc. Key Financial Metrics
- Market Cap: $4.74M
- Revenue: $N/A
- ROE: -314.89%
- ROIC: -122.18%
- Dividend Yield: N/A
About Imunon, Inc.
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.
Imunon, Inc. Investment Frameworks
Invetso analyzes Imunon, Inc. (IMNN) across the following frameworks:
- Imunon, Inc. 10Y Growth Potential
- Imunon, Inc. Scenario Analysis
- Imunon, Inc. Risks & Opportunities
- Imunon, Inc. Economic Moat
- Imunon, Inc. Business Model
- Imunon, Inc. Management
- Imunon, Inc. SWOT Analysis
- Imunon, Inc. Porter's 5 Forces
- Imunon, Inc. PESTLE Analysis
- Imunon, Inc. ESG Analysis